This system was also used by us (Kabelitz group) to demonstrate the efficacy of a Her2-Vγ9 “tribody” construct in enhancing lysis of Her2-expressing pancreatic adenocarcinoma cells by Vγ9Vδ2 effector T cells (34). The gene discussed is ERBB2; the disease is pancreatic adenocarcinoma.